The medical technology company Zenicor reports both increased revenue and operating profit during the first quarter compared with the same period last year. Revenue rose to SEK 7.8 million (7.1)."The growth during the year comes both from new customers and new agreements, as well as from our existing customers and license agreements. Several of our new deals follow the business model in which we are paid per completed patient investigation," comments CEO Mats Palerius.Operating profit was SEK 0.6 million (0.2), with an operating margin of 7.7 percent (2.8). Profit after tax was SEK 0.2 million (-0.5), and per share SEK 0.01 (-0.05).Focus markets are Sweden, Finland and the United Kingdom."These are the markets that during 2026 and 2027 will generate the growth that takes us to the next level," says Palerius.Zenicor, SEK millionQ1-2026Q1-2025ChangeNet sales7.87.19.9%Operating profit0.60.2200.0%Operating margin7.7%2.8%Net profit0.2-0.5Earnings per share, SEK0.01-0.05